Drugs / MB11
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07221734 | Dec 2025 → Apr 2027 expected | melanoma | mAbxience Research S.L. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07221734 ↗ |
| Route | Intravenous | “3 mg/kg IV infusion” NCT07221734 ↗ |